Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor in Heart Transplant Recipients with Chronic Kidney Disease
Abstract
Chronic kidney disease (CKD) is a major long-term complication following heart transplantation (HT). The safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for HT recipients with CKD remains unclear. We retrospectively reviewed the records of HT recipients who were followed up between April 2017 and December 2024 at our hospital; those with CKD who initiated SGLT2i at least 6 months after HT and had available follow-up data for 6 subsequent months were included. Among 91 patients who initiated SGLT2i, 45 were eligible (median age: 50 [47-59] years; 11 (24.4%) female). The median estimated glomerular filtration rate (eGFR) at SGLT2i initiation was 42.9 [33.8-50.6] mL/minute/1.73 m2. All patients continued SGLT2i without adverse events. Relative change in eGFR improved significantly from -9.1% in the 6 months before SGLT2i to +3.7% in the 6 months after (P = 0.043). Uric acid and hemoglobin levels improved (P < 0.001 and 0.002, respectively). Patients were stratified into 2 groups based on the relative change in eGFR to identify factors associated with improvement: those with a positive change (n = 23) and those without (n = 22). In logistic regression analysis adjusting for age and sex, lower eGFR (odds ratio: 1.09, 95% confidence interval: 1.02-1.15, P = 0.013) and non-ischemic etiology of heart failure (odds ratio: 18.9, 95% confidence interval: 1.66-215.0, P = 0.018) were associated with eGFR improvement after SGLT2i initiation. SGLT2i use appears…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 91 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.